CD8A and melanoma: In the same year, Fourcade et al. validated these results in patients with melanoma and also found that PD1 + TIM3 + CD8+ T cells had poorer function and produced lower levels of IFN-γ, TNF, and IL-2, than TIM3-PD1+ and TIM3-PD1-CD8+ T cells.